These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 15175148)

  • 1. Ocular allergy treatment comparisons: azelastine and olopatadine.
    Bielory L; Buddiga P; Bigelson S
    Curr Allergy Asthma Rep; 2004 Jul; 4(4):320-5. PubMed ID: 15175148
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A review of olopatadine for the treatment of ocular allergy.
    Abelson MB
    Expert Opin Pharmacother; 2004 Sep; 5(9):1979-94. PubMed ID: 15330735
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the efficacy of olopatadine hydrochloride 0.1% ophthalmic solution and azelastine hydrochloride 0.05% ophthalmic solution in the conjunctival allergen challenge model.
    Spangler DL; Bensch G; Berdy GJ
    Clin Ther; 2001 Aug; 23(8):1272-80. PubMed ID: 11558863
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effects of the nasal antihistamines olopatadine and azelastine in nasal allergen provocation.
    Pipkorn P; Costantini C; Reynolds C; Wall M; Drake M; Sanico A; Proud D; Togias A
    Ann Allergy Asthma Immunol; 2008 Jul; 101(1):82-9. PubMed ID: 18681089
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Olopatadine: a drug for allergic conjunctivitis targeting the mast cell.
    Leonardi A; Quintieri L
    Expert Opin Pharmacother; 2010 Apr; 11(6):969-81. PubMed ID: 20307221
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Olopatadine].
    Taéron C
    Rev Infirm; 2004 Apr; (100):43-4. PubMed ID: 15222186
    [No Abstract]   [Full Text] [Related]  

  • 7. Comparison of the efficacy of combined fluticasone propionate and olopatadine versus combined fluticasone propionate and fexofenadine for the treatment of allergic rhinoconjunctivitis induced by conjunctival allergen challenge.
    Lanier BQ; Abelson MB; Berger WE; Granet DB; D'Arienzo PA; Spangler DL; Kägi MK
    Clin Ther; 2002 Jul; 24(7):1161-74. PubMed ID: 12182260
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacotherapy of allergic eye disease.
    Manzouri B; Flynn TH; Larkin F; Ono SJ; Wyse R
    Expert Opin Pharmacother; 2006 Jun; 7(9):1191-200. PubMed ID: 16732705
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A review of the use of olopatadine in allergic conjunctivitis.
    McGill JI
    Int Ophthalmol; 2004 May; 25(3):171-9. PubMed ID: 15847317
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Topical antihistamines, mast cell stabilizers, and dual-action agents in ocular allergy: current trends.
    Ben-Eli H; Solomon A
    Curr Opin Allergy Clin Immunol; 2018 Oct; 18(5):411-416. PubMed ID: 30020258
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Double-masked, randomized, placebo-controlled clinical study of the mast cell-stabilizing effects of treatment with olopatadine in the conjunctival allergen challenge model in humans.
    Leonardi A; Abelson MB
    Clin Ther; 2003 Oct; 25(10):2539-52. PubMed ID: 14667955
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative efficacy of topical antihistamines in an animal model of early phase allergic conjunctivitis.
    Sanchis-Merino ME; Montero JA; Ruiz-Moreno JM; Rodriguez AE; Pastor S
    Exp Eye Res; 2008 May; 86(5):791-7. PubMed ID: 18378229
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mast cell stabilization and anti-histamine effects of olopatadine ophthalmic solution: a review of pre-clinical and clinical research.
    Rosenwasser LJ; O'Brien T; Weyne J
    Curr Med Res Opin; 2005 Sep; 21(9):1377-87. PubMed ID: 16197656
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Olopatadine 0.2% ophthalmic solution: the first ophthalmic antiallergy agent with once-daily dosing.
    Abelson MB; Gomes PJ
    Expert Opin Drug Metab Toxicol; 2008 Apr; 4(4):453-61. PubMed ID: 18433347
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Olopatadine hydrochloride ophthalmic solution for the treatment of allergic conjunctivitis.
    Gonzalez-Estrada A; Reddy K; Dimov V; Eidelman F
    Expert Opin Pharmacother; 2017 Aug; 18(11):1137-1143. PubMed ID: 28656804
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical and clinical antiallergic effect of olopatadine 0.2% solution 24 hours after topical ocular administration.
    Vogelson CT; Abelson MB; Pasquine T; Stephens DM; Gamache DA; Gross RD; Robertson SM; Yanni JM
    Allergy Asthma Proc; 2004; 25(1):69-75. PubMed ID: 15055565
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison of the efficacy and tolerability of olopatadine hydrochloride 0.1% ophthalmic solution and cromolyn sodium 2% ophthalmic solution in seasonal allergic conjunctivitis.
    Katelaris CH; Ciprandi G; Missotten L; Turner FD; Bertin D; Berdeaux G;
    Clin Ther; 2002 Oct; 24(10):1561-75. PubMed ID: 12462286
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological, pharmacokinetic and clinical properties of olopatadine hydrochloride, a new antiallergic drug.
    Ohmori K; Hayashi K; Kaise T; Ohshima E; Kobayashi S; Yamazaki T; Mukouyama A
    Jpn J Pharmacol; 2002 Apr; 88(4):379-97. PubMed ID: 12046981
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the efficacy and tolerability of topically administered azelastine, sodium cromoglycate and placebo in the treatment of seasonal allergic conjunctivitis and rhino-conjunctivitis.
    James IG; Campbell LM; Harrison JM; Fell PJ; Ellers-Lenz B; Petzold U
    Curr Med Res Opin; 2003; 19(4):313-20. PubMed ID: 12841924
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized, double-masked comparison of olopatadine ophthalmic solution, mometasone furoate monohydrate nasal spray, and fexofenadine hydrochloride tablets using the conjunctival and nasal allergen challenge models.
    Spangler DL; Abelson MB; Ober A; Gotnes PJ
    Clin Ther; 2003 Aug; 25(8):2245-67. PubMed ID: 14512132
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.